In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer

Linda K Rushworth; Victoria Harle; Peter Repiscak; William Clark; Robin Shaw; Holly Hall; Martin Bushell; Hing Y Leung; Rachana Patel

doi:10.26508/lsa.202000770

Research Article

Open Access

In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer

Linda K Rushworth, Victoria Harle, Peter Repiscak, William Clark, Robin Shaw, View ORCID ProfileHolly Hall, Martin Bushell, View ORCID ProfileHing Y Leung Correspondence email, Rachana Patel

Linda K Rushworth

1Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Victoria Harle

1Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Peter Repiscak

1Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

William Clark

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Robin Shaw

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Holly Hall

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Holly Hall

Martin Bushell

1Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hing Y Leung

1Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Hing Y Leung
For correspondence: h.leung@beatson.gla.ac.uk

Rachana Patel

2Cancer Research UK Beatson Institute, Glasgow, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Published 8 October 2020. DOI: 10.26508/lsa.202000770

Article
Figures & Data
Info
Metrics
Reviewer Comments
PDF

PreviousNext

Download PDF

Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer

Message Subject (Your Name) has sent you a message from Life Science Alliance

Message Body (Your Name) thought you would like to see the Life Science Alliance web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

In vivo CRISPR screen identifies TCEAL1 to enhance docetaxel

Linda K Rushworth, Victoria Harle, Peter Repiscak, William Clark, Robin Shaw, Holly Hall, Martin Bushell, Hing Y Leung, Rachana Patel

Life Science Alliance Oct 2020, 3 (12) e202000770; DOI: 10.26508/lsa.202000770

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

In vivo CRISPR screen identifies TCEAL1 to enhance docetaxel

Linda K Rushworth, Victoria Harle, Peter Repiscak, William Clark, Robin Shaw, Holly Hall, Martin Bushell, Hing Y Leung, Rachana Patel

Life Science Alliance Oct 2020, 3 (12) e202000770; DOI: 10.26508/lsa.202000770

Share This Article:

Tweet Widget

In this Issue

Volume 3, No. 12

December 2020

Table of Contents
Cover (PDF)
About the Cover
Masthead (PDF)

Jump to section

Article
Figures & Data
Info
Metrics
Reviewer Comments
PDF

Subjects

Cancer

No related articles found.

Cited By...

No citing articles found.

Google Scholar

Main menu

User menu

Search

In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer

Citation Manager Formats

In this Issue

Subjects

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Content

For Authors

Other Services

More Information